ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: A MICHELANGO study.
2016 ◽
Vol 34
(15_suppl)
◽
pp. 502-502
◽
Keyword(s):
2005 ◽
Vol 23
(16_suppl)
◽
pp. 789-789
◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 587-587
◽
2007 ◽
Vol 25
(18_suppl)
◽
pp. 517-517
◽
Keyword(s):
2010 ◽
Vol 28
(18)
◽
pp. 2958-2965
◽
2015 ◽
Vol 150
(3)
◽
pp. 605-611
◽
Keyword(s):
2014 ◽
Vol 32
(15_suppl)
◽
pp. 1010-1010
◽
Keyword(s):
2014 ◽
Vol 32
(15_suppl)
◽
pp. 504-504
◽
Keyword(s):
2016 ◽
Vol 34
(15_suppl)
◽
pp. 1002-1002
◽
Keyword(s):
2004 ◽
Vol 22
(14_suppl)
◽
pp. 587-587